



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/935,430	08/22/2001	Mary Faris	511582005000	9082

36327 7590 10/15/2003

AGENSYS C/O MORRISON & FOERSTER LLP
3811 VALLEY CENTRE DRIVE, SUITE 500
SAN DIEGO, CA 92130

EXAMINER

HARRIS, ALANA M

ART UNIT PAPER NUMBER

1642

DATE MAILED: 10/15/2003

15

Please find below and/or attached an Office communication concerning this application or proceeding.



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

DEA/FCE-1994

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.

EXAMINER	
Alana M. Harris, Ph.D.	
ART UNIT	PAPER NUMBER
1642	15

DATE MAILED:

Please find below a communication from the EXAMINER in charge of this application

Commissioner of Patents

1. This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 C.F.R. § 1.821(a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 C.F.R. §§ 1.821-1.825.

Applicants have elected Group XIII corresponding to claims 19, 21-24 and 67 that contain reference to a protein sequence. However, the protein has not been identified by SEQ ID number. Accordingly, it follows that the application is not compliant with sequence rules, see MPEP § 2421.02. The response filed August 12, 2003 as Paper number 14 will be held in abeyance until Applicants comply with the requirements of the sequence rules. Claim amendments inclusive of SEQ ID numbers should be fully supported by the specification and not representative of new matter. Applicants' attention is also directed to C.F.R. 1.121, Manner of Making Amendments.

2. Any inquiry concerning this communication should be directed to Examiner Alana M. Harris, Art Unit 1642, whose telephone number is (703)306-5880.
3. Any questions regarding compliance with the sequence rules requirements specifically should be directed to the departments listed:
For Rules Interpretation, call (703)308-4216;
For CRF Submission Help, call (703)308-4212; and /or
For PatentIn software help, call (703)308-6856.
4. APPLICANT IS GIVEN ONE MONTH FROM THE DATE OF THIS LETTER WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 C.F.R. §§ 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of the application under 37 C.F.R. § 1.821(g). Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 C.F.R. § 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Direct the response to the undersigned. Applicant is requested to return a copy of the attached Notice to Comply with the response.

Alana M. Harris, Ph.D.

ALANA M. HARRIS, PH.D.

PRIMARY EXAMINER

10/8/2003